论文部分内容阅读
目的:对反流性食管炎患者应用雷贝拉唑钠肠溶片联合多潘立酮治疗的效果及方案的安全性进行探讨。方法:选取东城人民医院2015年3月至2017年3月收治的反流性食管炎患者共105例,观察组55例给予雷贝拉唑钠肠溶片联合多潘立酮治疗,对照组50例给予雷贝拉唑钠肠溶片治疗,对两组治疗效果、并发症发生率展开评估,总结治疗经验。结果:观察组治疗总有效率为98.18%,显著高于对照组的80.00%,差异具有统计学意义(P<0.05)。观察组并发症发生率为3.64%,对照组并发症发生率为20.00%,组间比较,差异具有统计学意义(P<0.05)。结论:保证方案安全的基础上,为了增进治疗效果,建议临床采用雷贝拉唑钠肠溶片联合多潘立酮治疗反流性食管炎。
OBJECTIVE: To evaluate the efficacy and safety of rabeprazole sodium enteric-coated tablets combined with domperidone in patients with reflux esophagitis. Methods: A total of 105 patients with reflux esophagitis were selected from Dongcheng People’s Hospital from March 2015 to March 2017. 55 cases in the observation group were given rabeprazole sodium enteric-coated tablets combined with domperidone, while 50 cases in the control group were given Lei Beirazole sodium enteric-coated tablets treatment, the two groups of treatment effects, the incidence of complications to evaluate, summarize the treatment experience. Results: The total effective rate of the observation group was 98.18%, which was significantly higher than that of the control group (80.00%), the difference was statistically significant (P <0.05). The incidence of complications in the observation group was 3.64%, and the incidence of complications in the control group was 20.00%. The differences between the two groups were statistically significant (P <0.05). Conclusion: On the basis of ensuring the safety of the regimen, in order to improve the curative effect, it is recommended that rabeprazole sodium enteric-coated tablets and domperidone be used in the treatment of reflux esophagitis.